Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey

Basit Öğe Kaydı
dc.authoridNuri Faruk Aykan / 0000-0002-5472-3218en_US
dc.authorscopusidNuri Faruk Aykan / 57219836263
dc.authorwosidNuri Faruk Ayhan / I-6425-2019en_US
dc.contributor.authorÖzet, Ahmet
dc.contributor.authorDane, Faysal
dc.contributor.authorAykan, Nuri Faruk
dc.contributor.authorYalçın, Şuayib
dc.contributor.authorEvrensel, Türkkan
dc.contributor.authorÖzkan, Metin
dc.contributor.authorKarabulut, Bülent
dc.contributor.authorÖrmeci, Merve Nur
dc.contributor.authorAtasev, Ozan
dc.contributor.authorVidot, Loick
dc.date.accessioned2022-09-15T12:58:08Z
dc.date.available2022-09-15T12:58:08Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractBackground: The efficacy and safety of trifluridine/tipiracil (FTD/TPI) for third-line treatment of metastatic colorectal cancer have been demonstrated. The authors present the Turkish post hoc analysis of the PRECONNECT study. Methods: An international, multicenter, single-arm, open-label, phase IIIb trial evaluating FTD/TPI in patients with >= 2 previous lines of chemotherapy for metastatic colorectal cancer was conducted. The primary end point was safety. Results: In this Turkish cohort (n = 100; eight centers), the most frequent treatment-emergent adverse event was neutropenia (48%). Median progression-free survival was 3.0 months; disease control rate was 36%; quality of life remained stable. Conclusion: Outcomes with FTD/TPI in Turkey are consistent with previous studies and confirm the efficacy and safety of FTD/TPI treatment in the third-line setting.en_US
dc.identifier.citationOzet, A., Dane, F., Aykan, N. F., Yalcin, S., Evrensel, T., Ozkan, M., Karabulut, Bu., Ormeci, M. N., Atasev, O., Vidot, L. (2022). Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey. Future Oncology.en_US
dc.identifier.doi10.2217/fon-2022-0455en_US
dc.identifier.issn1479-6694en_US
dc.identifier.scopus2-s2.0-85140272327en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.uridoi. org/10.2217/fon-2022-0455
dc.identifier.urihttps://hdl.handle.net/20.500.12713/3141
dc.identifier.wosWOS:000847506600001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorAykan, Nuri Faruk
dc.language.isoenen_US
dc.publisherFUTURE MEDICINEen_US
dc.relation.ispartofFUTURE ONCOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMetastatic Colorectal Canceren_US
dc.subjectPRECONNECT Studyen_US
dc.subjectReal-World Dataen_US
dc.subjectTrifluridine/Tipiracilen_US
dc.subjectTurkish Populationen_US
dc.titleSafety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkeyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
fon-2022-0455.pdf
Boyut:
1.57 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu